Perceived Outcomes and Barriers of Advance Care Planning from Healthcare Professionals

Advance care planning (ACP) is the process of aligning patients’ values and preferences to their future medical care. ACP is important in promoting patient autonomy and helping patients and their families prepare for end-of-life conversations. Healthcare teams, made up of physicians, nurses, or social workers, carry the responsibility to engage patients into such conversations. The purpose of this study was to explore the perceptions and experiences of healthcare professionals regarding ACP outcomes and barriers. This cross- sectional study used survey responses of a convivence sample of 18 allied healthcare professionals and 4 physicians in a not-for-profit, faith-based hospital system in West Texas to measure willingness, confidence, and participation in ACP, and barriers related to those outcomes as professionals. This study found moderate to high mean ratings for ACP outcomes for physicians and allied healthcare professionals. The regression analysis showed allied healthcare professionals who perceived higher barriers in their roles had lower confidence in engaging in ACP with patients. From the current study and analyzed literature, the researcher suggests healthcare professionals need to have opportunities to expand their knowledge and confidence in ACP conversations to promote better patient outcomes in end-of-life care

Managing Qualtrics Survey Distributions and Response Data with SAS®

Managing multiple surveys and distributing them to several research participants at multiple time intervals can be tedious and time consuming. Qualtrics is an online survey tool that offers a variety of features that could be useful for researchers. By using SAS to interface with the Qualtrics REST API, and SAS XML Mapper to generate the XML maps from the XML responses, we were able to implement an effective system that enabled survey data to be accessed regularly, accurately scheduled the distribution of surveys to research participants, and prevented withdrawn participants from receiving scheduled emails. In this paper, we demonstrate how to implement the submit API requests with the FILENAME statement (URL access method) and process API responses with SAS® XML Mapper. Additionally we describe an approach for tracking active and inactive respondents

Using SAS® Arrays to Calculate Bouts of Moderate to Vigorous Physical Activity from Minute-by-Minute Fitbit Data

The increasing popularity and affordability of wearable fitness tracking devices, together with their ability to provide granular physical activity data down to the minute-level, has enabled researchers to conduct advanced studies on the effects of physical activity on health and disease. This technology also provides statistical programmers the challenge of processing these data and translating them into analyzable measures. One such measure is the number of time-specific bouts of moderate to vigorous physical activity (MVPA), (akin to ‘exercise’) which is needed to determine if the participant meets current physical activity guidelines (e.g.,150 min.of MVPA/week performed in bouts of at least 10 min.). In this paper, we illustrate how we used SAS® arrays to calculate the number of 10-min.bouts of MVPA per day and provide a working code that can be run on a sample file

Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis

Introduction Improved nutrition is the major proven benefit of newborn screening programmes for cystic fibrosis (CF) and is associated with better clinical outcomes. It was hypothesised that early pulmonary inflammation and infection in infants with CF is associated with worse nutrition. Methods Weight, height and pulmonary inflammation and infection in bronchoalveolar lavage (BAL) were assessed shortly after diagnosis in infants with CF and again at 1, 2 and 3 years of age. Body mass index (BMI) was expressed as z-scores. Inflammatory cells and cytokines (interleukin 1b (IL-1b), IL-6, IL-8 and tumour necrosis factor a (TNFa)), free neutrophil elastase activity and myeloperoxidase were measured in BAL. Mixed effects modelling was used to assess longitudinal associations between pulmonary inflammation, pulmonary infection (Staphylococcus aureus and Pseudomonas aeruginosa) and BMI z-score after adjusting for potential confounding factors. Results Forty-two infants were studied (16 (38%) male; 39 (93%) pancreatic insufficient); 36 were diagnosed by newborn screening (at median age 4 weeks) and six by early clinical diagnosis (meconium ileus). Thirty-one (74%) received antistaphylococcal antibiotics. More than two-thirds were asymptomatic at each assessment. Mean BMI z-scores wer

Dimensional structure and correlates of posttraumatic stress symptoms following suspected acute coronary syndrome

Background Posttraumatic stress disorder (PTSD) is a heterogeneous construct, and some have suggested that PTSD triggered by acute coronary syndrome (ACS) may differ from PTSD due to prototypical traumas. Methods We conducted the first examination of the latent structure of PTSD symptoms after suspected ACS in 399 adults in the REactions to Acute Care and Hospitalization (REACH) study, an observational cohort study of patients recruited from the emergency department during evaluation for ACS. Using confirmatory factor analysis, we compared the 4-factor dysphoria, 4-factor numbing, and 5-factor dysphoric arousal models of PTSD. Results Although all models fit well, the dysphoria model was selected as the best-fitting model. Further, there was measurement invariance of the dysphoria model by sex. PTSD dimensions evidenced differential associations with indicators of threat perception during ACS evaluation and adherence to cardioprotective medication. Limitations One limitation of this investigation is the use of self-report measures. In addition, only one-third of the sample was diagnosed with ACS at discharge; the remaining participants received diagnoses such as chest pain without a cardiac diagnosis, another symptom/disease process (e.g., hypertensive chronic kidney disease), or another cardiac disease. Conclusions Findings suggest that suspected ACS-related PTSD symptoms are best-represented by a 4-factor structure distinguishing between specific (e.g., re-experiencing) and non-specific (dysphoria) symptoms of PTSD that has received support in the broader PTSD literature

Comparison of Different Algorithms for Sentiment Analysis: Psychological Stress Notes

To visualize and compare three text analysis algorithms of sentiment (AFINN, Bing, Syuzhet), applied to 1549 ecologically assessed self-report stress notes obtained by smartphone, in order to gain insights about stress measurement and management

Treatment rates for PTSD and depression in recently hospitalized cardiac patients

Objective Posttraumatic stress disorder (PTSD) and depression are common after evaluation for suspected acute coronary syndrome (ACS), and are associated with poor prognosis. However, it is unclear whether patients discharged after suspected ACS access treatments for subsequent psychological distress. We examined self-reported rates of receiving psychotherapy and/or medication for psychological distress in patients one month after a suspected ACS event. Methods A sample of 448 adults (age 60.4 ± 12.5; 47.8% female; 52.7% Hispanic, 32.1% Black) presenting to the emergency department with suspected ACS were recruited for the REactions to Acute Care and Hospitalization (REACH) study, an ongoing cohort study of medical and psychological outcomes after ACS evaluation. Socio-demographics and depressive symptoms were assessed in-hospital, and PTSD symptoms related to the suspected ACS event were queried via phone one month after enrollment. Participants also indicated whether they received either medication or counseling to deal with their emotions and coping after their heart problem. Results Approximately 15% (n = 68) of the sample reported receiving some form of treatment. Treatment rate did not differ significantly as a function of demographics, ACS status, or insurance coverage, ps > 0.1. Over a quarter of participants (25.3%) who screened positive for PTSD and/or depression reported receiving treatment. Participants with PTSD and depression had a higher treatment rate (47.6%) vs. those with only depression (12.8%) or PTSD (30%) or no psychopathology (10.3%). Conclusion Findings suggest that 1 in 4 patients who screened positive for PTSD and/or depression reported receiving counseling or medication in the first month after a suspected ACS event

Clinical Usefulness of Bright White Light Therapy for Depressive Symptoms in Cancer Survivors: Results from a Series of Personalized (N-of-1) Trials

Publisher's version (útgefin grein)Purpose: Little is known about the effectiveness of bright white light therapy (BWL) for depressive symptoms in cancer survivors, many of whom prefer non-pharmacological treatments. The purpose of this study was to compare the effectiveness of BWL versus dim red light therapy (DRL) on depressive symptoms within individual cancer survivors using personalized (N-of-1) trials. Methods: Cancer survivors with at least mild depressive symptoms were randomized to one of two treatment sequences consisting of counterbalanced crossover comparisons of three-weeks of lightbox-delivered BWL (intervention) or DRL (sham) for 30 min each morning across 12 weeks. A smartphone application guided cancer survivors through the treatment sequence and facilitated data collection. Cancer survivors tracked end-of-day depressive symptoms (primary outcome) and fatigue using visual analog scales. Within-patient effects of BWL were assessed using an autoregressive model with adjustment for linear time trends. Results: Eight of nine cancer survivors completed the 12-week protocol. Two survivors reported significantly (i.e., p < 0.05) lower depressive symptoms (-1.3 +/- 0.5 and -1.30 +/- 0.9 points on a 10-point scale), five reported no difference in depressive symptoms, and one reported higher depressive symptoms (+1.7 +/- 0.6 points) with BWL versus DRL. Eight of nine cancer survivors recommended personalized trials of BWL to others. Conclusions: There were heterogeneous effects of three-week BWL on self-reported depressive symptoms among cancer survivors, with some finding a benefit but others finding no benefit or even harm. Implications for Cancer Survivors: Personalized trials can help cancer survivors learn if BWL is helpful for improving their depressive symptoms.This research was funded in part with Federal funds from the National Cancer Institute, NIH, under Contract No. HHSN261200800001E. Drs. Kronish, Davidson, and Cheung received additional support from the National Library of Medicine (R01LM012836)."Peer Reviewed

Design and baseline data from the vanguard of the Comparison of Depression Interventions after Acute Coronary Syndrome (CODIACS) randomized controlled trial

This paper describes the rationale and design of the vanguard for the Comparison of Depression Interventions after Acute Coronary Syndrome (CODIACS), a multicenter, randomized, controlled trial of a patient preference‐based, stepped care protocol for persistent depressive symptoms after acute coronary syndrome (ACS). The overall aim of the vanguard phase was to determine whether the patient-preference, stepped care protocol, which is based on the intervention used in the recent Coronary Psychosocial Evaluation Studies (COPES) trial, was feasible in patients with recent ACS who were recruited from 5 geographically diverse sites. Innovative design features of this trial include randomization to either initial patient-preference of treatment or to a referred care arm in which the primary care provider decided upon care. Additionally, delivery of psychotherapy was accomplished by telephone, or webcam, depending upon patient preference. The vanguard phase provides estimates of eligibility and screening/enrollment ratios, patient acceptance of screening, and retention. In this report, we describe the innovative features and the baseline results of the vanguard phase of CODIACS. The data from this vanguard study will be used to finalize planning for a large, phase III clinical trial designed to evaluate the effect of treatment on depressive symptoms, coronary events, and death

Centralized, Stepped, Patient Preference–Based Treatment for Patients With Post–Acute Coronary Syndrome Depression

IMPORTANCE: Controversy remains about whether depression can be successfully managed after acute coronary syndrome (ACS) and the costs and benefits of doing so. OBJECTIVE: To determine the effects of providing post-ACS depression care on depressive symptoms and health care costs. DESIGN: Multicenter randomized controlled trial. SETTING: Patients were recruited from 2 private and 5 academic ambulatory centers across the United States. PARTICIPANTS: A total of 150 patients with elevated depressive symptoms (Beck Depression Inventory [BDI] score ≥10) 2 to 6 months after an ACS, recruited between March 18, 2010, and January 9, 2012. INTERVENTIONS: Patients were randomized to 6 months of centralized depression care (patient preference for problem-solving treatment given via telephone or the Internet, pharmacotherapy, both, or neither), stepped every 6 to 8 weeks (active treatment group; n = 73), or to locally determined depression care after physician notification about the patient's depressive symptoms (usual care group; n = 77). MAIN OUTCOME MEASURES: Change in depressive symptoms during 6 months and total health care costs. RESULTS: Depressive symptoms decreased significantly more in the active treatment group than in the usual care group (differential change between groups, -3.5 BDI points; 95% CI, -6.1 to -0.7; P = .01). Although mental health care estimated costs were higher for active treatment than for usual care, overall health care estimated costs were not significantly different (difference adjusting for confounding, -$325; 95$2639 to $1989; P = .78). CONCLUSIONS: For patients with post-ACS depression, active treatment had a substantial beneficial effect on depressive symptoms. This kind of depression care is feasible, effective, and may be cost-neutral within 6 months; therefore, it should be tested in a large phase 3 pragmatic trial. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01032018